CD8A and neoplasm: The interaction between TIM3 and galectin 9 (Gal9) in CD8+ T cells leads to the reduction of the production of cytokines (IFNγ, IL-2, and TNFα), the inhibition of T cell proliferation, and the inhibition of anti-tumor immunity (174).